<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is among the most common <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> worldwide </plain></SENT>
<SENT sid="1" pm="."><plain>Understanding <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> prognosis at the initial diagnosis is very important for therapeutic strategy selection </plain></SENT>
<SENT sid="2" pm="."><plain>This study was conducted to evaluate the prognostic value of preoperative serum carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA) and carbohydrate antigen 125 (CA125) for predicting 5-year recurrence-free survival (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e>) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Preoperative serum CA19-9, CEA and CA125 levels were detected by C12 protein chip diagnostic system in 103 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, and their correlations with the 5-year <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e> were analyzed </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Patients with positive preoperative serum CA19-9, CEA and CA125 had higher 5-year recurrent rates (75.0% vs 41.0%, 65.6% vs 39.4%, and 87.5% vs 44.2% respectively, <z:hpo ids='HP_0000001'>all</z:hpo> p&lt; (o)0.05), and reduced median <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e> (14 vs 35 months, 20 vs 36 months, and 4 vs 35 months respectively, <z:hpo ids='HP_0000001'>all</z:hpo> p&lt; (o)0.05) compared with patients negative for corresponding <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> marker (TM) </plain></SENT>
<SENT sid="5" pm="."><plain>The median <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e> was 59 months (95% CI 28.9-89.1 months) with negative TMs, 14 months (95% CI 4.5-23.5) for 1~2 positive TMs, and 4 months (95% CI 2.4-5.6) for <z:hpo ids='HP_0000001'>all</z:hpo> 3 positive TMs </plain></SENT>
<SENT sid="6" pm="."><plain>Patients with simultaneously positive serum CA19-9, CEA and CA125 had the highest recurrence rate (100%) and the shortest <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e> (median 4 months) </plain></SENT>
<SENT sid="7" pm="."><plain>Univariate analysis showed that stage and the preoperative single TM or combined TMs correlated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e>, whereas multivariate Cox regression model analysis revealed only stage and preoperative serum status of CEA+CA19-9+CA125 to be independent prognostic factors </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Preoperative serum CA19-9+CEA+CA125 can be used an independent prognostic factor for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> 5-year <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e> </plain></SENT>
</text></document>